

# Research Grade Diridavumab

#### Summary

Catalog No. DVV03801

Alternative Names CR-6261, CR6261, CAS: 1393659-46-5

Clone ID Diridavumab

Host species Human

Species reactivity Influenza A virus

Form Liquid

Storage buffer 0.01M PBS, pH 7.4.

Concentration 1.66 mg/ml

Purity >95% as determined by SDS-PAGE.

**Clonality** Monoclonal

Isotype IgG1, lambda

**Applications** Research Grade Biosimilar

Target HA/Hemagglutinin

**Purification** Protein A/G purified from cell culture supernatant.

Endotoxin level Please contact with the lab for this information.

**Expression system** Mammalian Cells

Accession P03455

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stability and Storage Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -

80°C long term.




Note

For research use only. Not suitable for clinical or therapeutic use.

## Description

Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).


## Data Image



SDS PAGE for Diridayumab



#### Recombinant Proteins & Antibodies



The purity of this product is >95% as determined by SEC-HPLC.